12 / 33
Olaparib significantly prolonged PFS in platinum-sensitive relapsed HGSOC
–
Patients with a
BRCA
mutation receive greater treatment benefit
–
Non-mutation carriers may also benefit from olaparib treatment
0
Time from randomization (months)
0
1.0
Proportion of patients
progression-free
3
6
9
12
15
Olaparib BRCAm
Olaparib BRCAwt
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
BRCAm (n=136)
BRCAwt (n=118)
Olaparib
Placebo
Olaparib
Placebo
Median PFS,
months
11.2
4.3
7.4
5.5
HR=0.18
P
<0.00001
HR=0.53
P
=0.007
Placebo BRCAm
Placebo BRCAwt
Ledermann
et al. N Eng J Med
2012. Ledermann
et al. Lancet Oncol
2014